DDInter1729 DDInter9
Sulindac is a nonsteroidal anti-inflammatory drug (NSAID) of the arylalkanoic acid class that is marketed by Merck under the brand name Clinoril. Like other NSAIDs, it may be used in the treatment of acute or chronic inflammatory conditions. Sulindac is a prodrug, derived from sulfinylindene, that is converted _in vivo_ to an active sulfide compound by liver enzymes. There is evidence from some studies that sulindac may be associated with fewer gastrointestinal side effects than other NSAIDs, except for the cyclooxygenase-2 (COX-2) inhibitor drug class. This may be due to the sulfide metabolite undergoing enterohepatic circulation thus maintaining constant blood levels of the compound without inducing gastrointestinal effects, where the drug is excreted in the bile and then reabsorbed from the intestines. While its full mechanism of action is not fully understood, sulindac
To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor indicated for the treatment of chronic lymphocytic leukemia, small lymphocytic lymphoma, and in adult patients with Mantle cell lymphoma (MCL) who have already received at least one prior therapy. In August 2022, the FDA approved a new tablet formulation of Calquence, enabling the co-administration of this drug with proton pump inhibitors (PPIs).[L42795,L42800] Unlike Calquence capsules, the co-administration of Calquence tablets and PPIs does not have an effect in the pharmacokinetics of acalabrutinib.[L10241,L42795] Also known as ACP-196, acalabrutinib is also considered a second generation BTK inhibitor because it was rationally designed to be more potent and selective than ibrutinib, theoretically expected to demonstrate fewer adverse effects owing to minimized bystander effects on targets other than BTK. Nevertheless, acalabrutinib was approved under the FDA's accelerated approval pathway, which is based upon overall response rate and faciliates earlier approval of medicines that treat serious conditions or/and that fill an unmet medical need based on a surrogate endpoint. Continued approval for acalabrutinib's currently accepted indication may subsequently be contingent upon ongoing verification and description of clinical benefit in confimatory trials. Furthermore, the FDA granted this medication Priority Review and Breakthrough Therapy designations. It also received Orphan Drug designation, which provides incentives to assist and encourage the development of drugs for rare diseases. At this time, more than 35 clinical trials across 40 countries with more than 2500 patients are underway or have been completed with regards to further research into better understanding and expanding the therapeutic uses of acalabrutinib .
Sulindac {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Nifedipine
Nifedipine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Acalabrutinib
Sulindac {u} (Compound) binds {v} (Gene) PTGDR2
PTGDR2 {u} (Gene) is bound by {v} (Compound) Indomethacin
Indomethacin {u} may lead to a major life threatening interaction when taken with {v} Acalabrutinib
Sulindac {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Rifabutin
Rifabutin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Acalabrutinib
Sulindac {u} (Compound) binds {v} (Gene) PTGS1
PTGS1 {u} (Gene) is bound by {v} (Compound) Flurbiprofen
Flurbiprofen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v} Acalabrutinib
Sulindac {u} (Compound) binds {v} (Gene) PPARD
PPARD {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is upregulated by {v} (Compound) Treprostinil
Treprostinil {u} may lead to a major life threatening interaction when taken with {v} Acalabrutinib
Sulindac {u} (Compound) palliates {v} (Disease) osteoarthritis
osteoarthritis {u} (Disease) is palliated by {v} (Compound) Ketoprofen
Ketoprofen {u} may lead to a major life threatening interaction when taken with {v} Acalabrutinib
Sulindac {u} (Compound) is included by {v} (Pharmacologic Class) Nonsteroidal Anti-inflammatory Compounds
Nonsteroidal Anti-inflammatory Compounds {u} (Pharmacologic Class) includes {v} (Compound) Oxaprozin
Oxaprozin {u} may lead to a major life threatening interaction when taken with {v} Acalabrutinib
Sulindac {u} (Compound) causes {v} (Side Effect) Alopecia
Alopecia {u} (Side Effect) is caused by {v} (Compound) Carbamazepine
Carbamazepine {u} may lead to a major life threatening interaction when taken with {v} Acalabrutinib
Sulindac {u} (Compound) is included by {v} (Pharmacologic Class) Nonsteroidal Anti-inflammatory Compounds
Nonsteroidal Anti-inflammatory Compounds {u} (Pharmacologic Class) includes {v} (Compound) Nepafenac
Nepafenac {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Acalabrutinib
Sulindac {u} (Compound) causes {v} (Side Effect) Alopecia
Alopecia {u} (Side Effect) is caused by {v} (Compound) Pentosan polysulfate
Pentosan polysulfate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Acalabrutinib
Sulindac (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Nifedipine (Compound) and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Sulindac (Compound) binds PTGDR2 (Gene) and PTGDR2 (Gene) is bound by Indomethacin (Compound) and Indomethacin may lead to a major life threatening interaction when taken with Acalabrutinib
Sulindac (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Rifabutin (Compound) and Rifabutin may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Sulindac (Compound) binds PTGS1 (Gene) and PTGS1 (Gene) is bound by Flurbiprofen (Compound) and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib and Flurbiprofen may lead to a major life threatening interaction when taken with Acalabrutinib
Sulindac (Compound) binds PPARD (Gene) and PPARD (Gene) is bound by Treprostinil (Compound) and PPARD (Gene) is upregulated by Treprostinil (Compound) and Treprostinil may lead to a major life threatening interaction when taken with Acalabrutinib
Sulindac (Compound) palliates osteoarthritis (Disease) and osteoarthritis (Disease) is palliated by Ketoprofen (Compound) and Ketoprofen may lead to a major life threatening interaction when taken with Acalabrutinib
Sulindac (Compound) is included by Nonsteroidal Anti-inflammatory Compounds (Pharmacologic Class) and Nonsteroidal Anti-inflammatory Compounds (Pharmacologic Class) includes Oxaprozin (Compound) and Oxaprozin may lead to a major life threatening interaction when taken with Acalabrutinib
Sulindac (Compound) causes Alopecia (Side Effect) and Alopecia (Side Effect) is caused by Carbamazepine (Compound) and Carbamazepine may lead to a major life threatening interaction when taken with Acalabrutinib
Sulindac (Compound) is included by Nonsteroidal Anti-inflammatory Compounds (Pharmacologic Class) and Nonsteroidal Anti-inflammatory Compounds (Pharmacologic Class) includes Nepafenac (Compound) and Nepafenac may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Sulindac (Compound) causes Alopecia (Side Effect) and Alopecia (Side Effect) is caused by Pentosan polysulfate (Compound) and Pentosan polysulfate may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib